Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Liquid Biopsies and Minimally-Invasive Diagnostics 2017

Robert Kinders's Biography



Robert Kinders, Sr. Principal Scientist and Head, Laboratory of Human Toxicology and Pharmacology, Frederick National Laboratory for Cancer Research

Robert Kinders is head of the Pharmacodynamics assay development (PADIS) laboratory at Frederick National Laboratory. The PADIS laboratory is charged with development and validation of assays to measure the effects, at the molecular level, of new, targeted anticancer agents in first-in-man clinical trials at the NCI Clinical Center. He received his Ph.D. in Biology at Kansas State University, and did post-doctoral studies at the University of Washington. His research has focused on cancer diagnostics and biomarkers. He has worked extensively in the U.S. Diagnostics Devices industry, including stints at Abbott Laboratories and C.R. Bard; and in pharmaceutical development at Abbott Laboratories and CuraGen.

Robert Kinders Image

Drug Pharmacodynamics in Clinical Trials by CTC Monitoring

Friday, 6 October 2017 at 16:00

Add to Calendar ▼2017-10-06 16:00:002017-10-06 17:00:00Europe/LondonDrug Pharmacodynamics in Clinical Trials by CTC MonitoringLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

The drug class being explored are nucleoside analogs being developed in the NCI NExT program.  The presentation will also include some data on changes in CTC phenotype, including EMT, during the course of therapy.


Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com